A Phase 1/2a, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of combinations of BMS-986507 (BL-B01D1) in adult participants with advanced solid tumors.
Contact Information for Access
Status
IN ATTIVAZIONE
Objective of the study
To evaluate the antitumor efficacy of PF-08634404 alone and in combination with ipilimumab.
To evaluate the safety and tolerability of PF-08634404 alone and in combination with ipilimumab.
To identify a recommended dose of PF-08634404 in combination with ipilimumab.
Hepatocellular carcinoma.
Medication
PF-08634404 as monotherapy versus standard combination therapy.
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with locally advanced or metastatic unresectable hepatocellular carcinoma.
Back to search page